Introduction {#sec1-1}
============

Asthma is a chronic disease characterized by recurrent attacks of breathlessness and wheezing, which vary in severity and frequency from person to person.\[[@ref1]\] WHO estimates show that 300 million people currently suffer from asthma. Asthma deaths will increase in the next 10 years if urgent action is not taken.\[[@ref2]\] Asthma cannot be cured, but proper diagnosis, treatment and patient education can result in good asthma control and management. Asthma occurs in all countries regardless of level of development. Over 80% of asthma deaths occur in low and lower-middle income countries. For effective control, it is essential to make medications affordable and available, especially for low-income families.\[[@ref3][@ref4]\]

On the basis of similar clinical features, Bronchial Asthma can be correlated with *Tamaka Shwasa*, a disease described under the heading of five types of *Shwasa* in Ayurvedic classics. According to Ayurveda *Shwasa* is a *Kapha-Vataja* disease, which is originated from *Pittasthana*.\[[@ref5]\] According to Ayurveda, formation of *Ama* is the seed for the development of future disease. The acute attack of disease appears whenever there is an obstruction of the normal passage of *Pranavayu*. Once the obstruction is removed, and *Vayu* start travelling in its normal path symptom, (breathlessness, cough etc.,) are abolished. Considering the Ayurvedic concept of treatment of *Tamaka Shwasa* it was decided to select an herbal Preparation "*Shirishadi* compound" for the management of bronchial asthma. The drug was decided to be given through nasal route followed by oral administration of the drug.

Administration of the drug through nasal route is known as *Nasya* in Ayurveda.\[[@ref6]\] Ayurveda emphasis more on Nasal delivery of drug in diseases related to *Shira* and *Pranavaha Srotasa*. The channels carrying *Pranavayu* are known as *Pranavaha Srotasa*, vitiation of *Pranavaha Srotasa* cause *Shwasa* (dyspnea). In the present trial, Nasal route of drug administration and its efficacy in the acute attack was assessed and compared with that of contemporary modern medicine. Desired to make some Ayurvedic preparation which is effective in controlling the acute attack of Asthma, having least toxic side effects, and efficacy equivalent to that of modern medicine inspire to plan the present research work.

Materials and Methods {#sec1-2}
=====================

Preparation of drug: *Shirishadi* compound {#sec2-1}
------------------------------------------

The plants *Albizia lebbeck* (L.) Benth., *Cyperus rotundus* Linn., and *Solanum xanthocarpum* Schrad and Wendl. were collected from the local market of Varanasi in equal quantity \[[Table 1](#T1){ref-type="table"}\]. Hydroalcoholic extraction (distilled water: ethanol = 2:1) of drugs was carried out by hot percolation method through Soxhlet apparatus. Thereafter, extracts were dried using a rotatory evaporator, and dried extract was again diluted to prepare a homogenous concentration of drug (1 mg/ml). Standardization of drug was done by using physical characterization, thin layer chromatography, and gas chromatography--mass spectrometry analysis.

###### 

Contents of *Shirishadi* polyherbal compound
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### Ayurvedic medication {#sec3-1}

For nebulization - Extract of *Shirishadi* compound 2.5 ml (1 mg/ml).Oral drug - *Shirishyadi Ghana Vati* (500 mg).

### Modern medication {#sec3-2}

For nebulization - a. Duoline (Levosalbutamol + Ipratropium Bromide) 2 mg in 1^st^ sub groupb. Budecort 2 mg in 2^nd^ sub group.Oral drug - Tablet Deriphyllin Retard (115 + 35 mg).

### Placebo therapy {#sec3-3}

For nebulization - Normal saline 2.5 mlOral drug - Sugar pills (inert placebo tablets).

Clinical trial {#sec2-2}
--------------

Human trial consist of Stage- I, II and III Clinical Study. The studies were carried out to determine the effective dose for the human being and to assess the safety and maximum tolerated dose in the human being.

### Stage -- I Clinical Study {#sec3-4}

For this study, five healthy individual were selected. 100 μl of water extract (prepared through decoction method) of *Shirishadi* mixture (*Shirishadi* Ayurvedic Nebulizer) dissolved in 1.5 ml of distilled water and was given twice in a day to five healthy individual for 5 days. Routine blood test, renal function test, and liver function test were done before and after administration of the drug.

No side effects as well as no abnormality in laboratory investigations was reported.

### Stage-II Clinical Study {#sec3-5}

Multiple ascending dose determination study

Five patients of bronchial asthma were selected for this study and the drug was given in the following ascending doses:

100 μl of extract dissolved in 1.5 ml of distilled water B.D. for 2 days200 μl extract dissolved in 1.5 ml of distilled water B.D. for 2 days400 μl extract dissolved in 1.5 ml of distilled water B.D. for 2 days600 μl extract dissolved in 1.5 ml of distilled water B.D. for 2 days800 μl extract dissolved in 1.5 ml of distilled water B.D. for 2 days1000 μl extract dissolved in 1.5 ml of distilled water B.D. for 2 days.

Followed by routine blood, renal function and liver function test. Spirometery and lung X-ray was also done.

### Dose determination of drug {#sec3-6}

On the basis of results obtained from Stage II clinical study the dose of drug was decide as 5 mg/daily in two divided doses.

### Stage-III Clinical Study {#sec3-7}

Total 60 cases of bronchial asthma aged 18 -- 60 years were selected from Outdoor/Indoor patient department wing of Department of Kayachikitsa, Faculty of Ayurveda, IMS, BHU, Varanasi.

Exclusion criteria {#sec2-3}
------------------

Patients having bronchial carcinoma, emphysema, chronic pulmonary obstructive disease, pleural effusion, tuberculosis, cardiac asthma, status asthmatics were excluded.

Study Design {#sec2-4}
------------

Randomized study (Simple Random Sampling/Unrestricted Random Sampling).

Trial Methodology {#sec2-5}
-----------------

Open clinical trial.

Grouping and posology {#sec2-6}
---------------------

Total 60 clinically diagnosed patients of bronchial asthma were randomly divided into three groups:

### Group 1 {#sec3-8}

20 registered patients were administered *Shirishadi* Ayurvedic Nebulizer, 2.5 mg (2.5 ml) twice in a day for first 15 days and then S.O.S, followed by oral administration of *Shirishadi Ghana Vati* - 500 mg with lukewarm water, twice in a day for 1-month.

### Group 2 {#sec3-9}

20 registered patients divided into two sub groups (10 in each) and were given Duoline (Levosalbutamol + Ipratropium Bromide) 2 mg twice in a day in one group and 2 mg of Budecort twice in a day in another group for 15 days followed by oral administration of Tablet Deriphyllin Retard (115 + 35 mg), twice in a day for 15 days and then S.O.S.

### Group 3 {#sec3-10}

20 registered patients will be administered 2.5 ml normal saline twice in a day for 15 days and one sugar pill (inert sugar placebo tablet) twice day for 15 days and then S.O.S. In this group only mild asthmatic patient with no complication were chosen to avoid any discomfort for the patients.

Follow-up studies {#sec2-7}
-----------------

All patients of three groups were regularly followed once after 15 days for 45 daysImprovement and other effects were noted downAll patients were asked to undergo laboratory investigations before and after the treatment and during follow-up period.

Duration of trial {#sec2-8}
-----------------

Duration of nebulization: 15 daysDuration of oral treatment: 30 daysTotal duration of treatment: 45 days.

### Statistical analysis {#sec3-11}

One-way analysis of variance (ANOVA), *post-hoc* test, Chi-square, Friedman test, Paired *t*-test were applied. To assess the effect of drugs from the baseline to different follow-ups in qualitative variables increment in asymptomatic plus mild cases were undertaken.

Observations and Results {#sec1-3}
========================

Effect of drug on dyspnea {#sec2-9}
-------------------------

Within the group, comparison by Friedman test shows a significant *P* value in G1 and G2 and between the group comparisons by Chi-square test shows significant *P* value in AT, F1 and F2. It\'s evident from the [Table 2](#T2){ref-type="table"}, that in G1, there is reduction in percentage of severe and agonizing cases from 42.4% and 26.3% (BT) to 26.3% and 5.3% (AT) and 15.8%, 5.3% at first follow-up (F1). In G2: Marked reduction is observed in the percentage of both severe and agonizing cases from 43.8% and 18.8% (BT) to 0.00%, which is greater than G1. Normal saline-treated group showed an increase in the percentage of severe and agonizing cases from 10.0% and 0.00% to 70.0% and 10.0%.

###### 

Effect of *Shirishadi* compound on dyspnea in bronchial asthma
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Effect of drug on cough {#sec2-10}
-----------------------

Within the group comparison by Friedman test shows a significant *P* value in G1 and G2 and between the group comparisons by Chi-square test shows significant *P* value in AT, F1, and F2. It\'s evident from the [Table 3](#T3){ref-type="table"} that in G1, there is increase in percentage of asymptomatic cases from 0.00% (BT) to 15.8% (AT) with the reduction in moderate and severe cases from 47.4% and 36.8% to 21.1 and 10.5%, respectively. Marked reduction is observed in the percentage of both moderate and severe cases from 56.3% and 31.3% (BT) to 6.3% and 0.00% in G2. Normal saline-treated group showed increase in percentage of severe cases from 0.00% to 20.0% and reduction in percentage of moderate cases from 80.0% to 60.0% showing that severity of symptom increases after treatment with normal saline.

###### 

Effect of *Shirishadi* compound on cough in bronchial asthma
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Effect of drug on expectoration {#sec2-11}
-------------------------------

Within the group comparison by Friedman test shows a significant *P* value in G1 and G2 and between the group comparisons by Chi-square test shows significant *P* value in AT, F1, and F2. It\'s evident from the [Table 4](#T4){ref-type="table"} that in G1, there is increase in percentage of asymptomatic cases from 15.8% (BT) to 47.4% (AT) with the reduction in moderate and severe cases from 21.1% and 5.3% to 10.5 and 0.00%, respectively. In G2, marked reduction is observed in the percentage of both moderate and severe cases from 43.8% and 50.0% (BT) to 6.3% and 0.00%. In G3, normal saline-treated group showed an increase in the percentage of severe cases from 0.00% to 20.0% and a reduction in the percentage of mild cases from 40.0% to 20.0%.

###### 

Effect of *Shirishadi* compound on expectoration in bronchial asthma
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Effect of drug on wheezing {#sec2-12}
--------------------------

Within the group comparison by Friedman test shows a significant *P* value in G1 andG2 and between the group comparisons by Chi-square test shows significant *P* value in AT, F1, and F2 \[[Table 5](#T5){ref-type="table"}\]. In G1, there is increase in percentage of asymptomatic cases from 15.8% (BT) to 47.4% (AT) with reduction in moderate and severe cases from 21.1% and 5.3% to 10.5% and 0.00% respectively. In G2, marked reduction is observed in percentage of severe cases from 50.0% (BT) to 6.3% (AT), whereas percentage of moderate cases mildly increase after treatment from 43.8% (BT) to 50.0% (AT), though the severity of symptom is greatly reduced in this group. In G3, normal saline-treated group showed increase in percentage of severe cases from 0.00% to 20.0% and reduction in percentage of mild cases from 40.0% to 20.0% showing that severity of symptom increases after treatment with normal saline.

###### 

Effect of *Shirishadi* compound on wheezing in bronchial asthma
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Effect of drug on frequency of attack {#sec2-13}
-------------------------------------

Within the group comparison by Friedman test shows a significant *P* value in G1 and G2 and between the group comparisons by Chi-square test shows highly significant *P* value in AT, F1 and F2 \[[Table 6](#T6){ref-type="table"}\]. In G1, there is increase in percentage of asymptomatic and mild cases from 0.00% and 26.3% (BT) to 26.3% and 57.9% (AT) with the significant reduction in severe cases from 52.6% to 0.00%. In G2, there is increase in percentage of asymptomatic and mild cases from 0.00% and 18.8% to 56.3% and 43.8% with the significant reduction in percentage of moderate and severe cases from 43.8% and 37.8% to 0.00% and 0.00%. In G3, there is a mild increase in the percentage of a moderate case after treatment with reduction in the percentage of mild cases.

###### 

Effect of *Shirishadi* compound on frequency of attack in bronchial asthma
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Effect of drug on paroxysms of dyspnea {#sec2-14}
--------------------------------------

Within the group comparison by Friedman test shows a significant *P* value in G1 and G2 and between the group comparisons by Chi-square test shows highly significant *P* value in AT, F1 and F2. It\'s evident from the [Table 7](#T7){ref-type="table"} that in G 1, there is increase in percentage of asymptomatic and mild cases from 0.00% (BT) to 84.2% and 15.8% (AT) with the reduction in moderate and severe cases from 26.3% and 73.7% (BT) to 0.00% (AT). In G2, there is an increase in the percentage of asymptomatic and mild cases from 0.00% and 0.00% to 62.5% and 37.5%. Significant reduction is observed in percentage of moderate and severe cases as 50.0% (BT) reduces to 0.00%. In G3, there is no significant observable change found in patients treated with normal saline.
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Effect of *Shirishadi* compound on paroxysms of dyspnea in bronchial asthma
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Effect of drug on peak expiratory flow rate {#sec2-15}
-------------------------------------------

The mean score of peak expiratory flow rate (PEFR) before treatment in G1, G2, and G3 was 120,138 and 141, respectively. There is highly significant increase in mean score after treatment in GI (210) and G2 (194), *P* \< 0.001. There is a decrease in mean score of PEFR in Group 3 \[[Table 8](#T8){ref-type="table"}\]. Within the group comparison by Paired *t*-test shows a significant difference in mean score between BT-AT, BT-F1, AT-F1, and AT-F2, *P* \< 0.001 in G1. In G2 significant difference is found in BT-AT, BT-F1, BT-F2, *P* \< 0.001 with insignificant change in AT-F1, AT-F2, *P* \> 0.005. In G5 insignificant change is found between BT-AT, BT-F1and BT-F2.
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Effect of *Shirishadi* compound on PEFR in bronchial asthma
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Between the groups comparison by one-way ANOVA shows insignificant *P* value in AT, whereas significant *P* value in F1 and F2. *Post-hoc* test shows significant pair (1,3), (2,3) in F1 and F2.

Effect of drug on forced vital capacity {#sec2-16}
---------------------------------------

The mean score of forced vital capacity (FVC) before treatment in G1 and G2 and G3 was 1.55, 1.18, and 1.07, respectively. There is a significant increase in mean after treatment in GI (2.16) and G2 (2.10), *P* \< 0.001. There is an insignificant change in mean score of FVC found in Group 3.

Within the group comparison by Paired *t*-test shows a significant increase in mean score in FVC between BT-AT, BT-F2, *P* \< 0.001 in G1. In G2 also a significant difference is found between BT-AT, BT-F1, BT-F2, AT-F1, and AT-F2, *P* \< 0.001. In Group 5, insignificant change is found between BT-AT, BT-F1, and BT-F2.

Between the groups comparison by one-way ANOVA shows highly significant *P* value in AT, F1 and F2. *Post-hoc* test shows significant pair (1,3), (2,3) in AT, F1 and F2 \[[Table 9](#T9){ref-type="table"}\].
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Effect of *Shirishadi* compound on forced vital capacity in bronchial asthma
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Effect of drug on forced expiratory volume {#sec2-17}
------------------------------------------

The mean score of forced expiratory volume in 1 s (FEV1) before treatment in G1, G2 and G3 was 1.45, 1.13, and 1.14, respectively. There is a significant increase in mean after treatment in GI (2.09), and G3 (1.60), *P* \< 0.001. There is an insignificant change in mean score of FEV1 found in Group 3.

Within the group comparison by Paired *t*-test shows a significant increase in mean score in FEV1 between BT-AT, BT-F2, AT-F2, *P* \< 0.001 in G1. In G2 also a significant difference is found between BT-AT, BT-F1, BT-F2, AT-F1, and AT-F2, *P* \< 0.001. In Group 3 insignificant change is found between BT-AT, BT-F1, and BT-F2. Between the groups comparison by one-way ANOVA shows highly significant *P* value in AT, F1, and F2. *Post-hoc* test shows significant pair (1,3), (2,3) in AT, F1, and F2 \[[Table 10](#T10){ref-type="table"}\].
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Effect of *Shirishadi* Ayurvedic compound on FEV in bronchial asthma

![](AYU-35-261-g010)

Discussion {#sec1-4}
==========

The clinical studies on subjective, objective, and laboratory parameters have revealed that patients treated with Duoline and Budecort Nebulizer had shown significant improvement initially but after prolonged use the progress become constant along with the drug dependence. Moreover, patients treated with Budecort showed some side effects such as leg cramps, dizziness, palpitation, acidity, and nervousness. The most striking fact observed in patients treated with modern medicine was a high rate of recurrence in symptoms. After completion of the course of medicine, patient gets the symptom of the disease reappeared within 10--15 days. Moreover, no improvement was observed in recurrence of the attack on exposure to allergens.

In the patients of bronchial asthma, treated with Ayurvedic nebulizer statistically significant improvement on various parameters was recorded after the course of the therapy. The patients showed faster relief in symptoms with no apparent toxic effects. The improvement in pulmonary function remained constant even after 1-month of discontinuation of drugs, that is, there was no rebound broncho-constriction. There was ≥20% improvement in PEER, measured just after the administration of the drug. The group treated with Ayurvedic medicine showed significant improvement in PFT evidenced by marked increase in FEV1, FVC and PEFR.

According to Acaraya Charaka *Shirisha* (*A. lebbeck*) is best *Vishaghna* that is, it is best antitoxin. It is selected for its *Vishaghna* property. Acharya Charaka told that the indigested food act as a toxin in the body (*Amavisha*).\[[@ref7]\] *Shirisha* is known for having antiallergic,\[[@ref8]\] antihistaminic and mast cell stabilizing properties\[[@ref9]\] anti-inflammatory\[[@ref10][@ref11]\] and antioxidant\[[@ref12]\] activity for which it is selected. *Nagarmotha* (*C. rotundus*) is known as best *Samgrahaka*, *Deepana*, and *Pachana* drug.\[[@ref13]\] It is also known to have antioxidant and anti-inflammatory properties.\[[@ref14][@ref15]\] *Kantakari* (*S. xanthocarpum*) is a potent drug used in the ailment of *Pranavaha Srotas Dusti* (*Shwasa*, *Kasa*). It has potent bronchodilator effect\[[@ref16]\] with antimicrobial\[[@ref17]\] and anti-inflammatory\[[@ref18][@ref19]\] properties. *Shirishadi* compound is mainly selected to evaluate the anti-allergic property of the drug and its action in atopic asthma and according to Ayurveda it is supposed to act on *Rasagata Ama*, increase the *Rasagni*.

As there was no significant change found in patients treated with normal saline, it can be said the effect produced by Ayurvedic drug was existent and not apparent or placebo effect. Reduction in erythrocyte sedimentation rate and eosinophil count was more prominent when the drugs was given through oral route than nasal administration of drug, suggesting that systemic effect of the drugs was more effective when given through oral route.\[[@ref20]\]

Conclusion {#sec1-5}
==========

It can be concluded that polyherbal compound *Shirishadi* has potent antiasthmatic activity. It can be further concluded that this polyherbal compound can be used as "Therapeutic Agents" in the management of an acute attack of asthma as well as chronic persistent asthma. The trial gives a direction for searching new route of herbal drug administration. In spite of limitations, the present study conducted entirely from the new angle. The study has yielded several useful observations and result which would definitely open new vistas for the future research workers of Ayurveda in general and respiratory disorders as particular.
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